Amgen

Merck

PD-1 Landscape Evolves as Subcutaneous Use Grows and Biosimilars Approach Across Solid Tumors

Amgen Shares May Be 49% Undervalued According to DCF Model

Amgen CEO Optimistic About Weight Loss Drug's Long-Term Efficacy

安进

Amgen's 15min chart sees MACD Death Cross, KDJ Death Cross trigger.

Truist Securities Maintains Hold Rating for Amgen, Raises Price Target to $319.00 USD

Catalyst<ul> <li>Fund flow analysis shows a positive trend across all order sizes indicating inflows of capital into AMGN.</li></ul>Risk<ul> <li>Technical indicators for AMGN show a weak market state with multiple bearish signals dominating recent analysis.</li> <li>Analyst ratings for AMGN are inconsistent with one Strong Buy and one Neutral rating highlighting differing views on its outlook.</li></ul>

Key Factors

Amgen's MariTide advances in obesity trials with CEO Bob Bradway highlighting its potential for long-term patient weight loss efficacy.Amgen's stock fell 0.38% on January 13, 2026, with a trading volume ranking 145th as investors weighed competitive challenges in the obesity drug market.Amgen's shares rose 1.44% on January 14, 2026, driven by progress in its MariTide trial and strategic positioning in GLP-1 therapies.Amgen's biosimilar ABP-243 is expected to see high adoption rates in the PD-1 landscape once approved, according to a Spherix Global Insights report.Amgen CEO Bob Bradway described 2026 as a "springboard year," emphasizing clinical milestones, strategic acquisitions, and pipeline growth.

Recent Updates

AMGN News